Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

Poster 421-P: ZDSD Rat Preclinical Model for Cardiomyopathy Drug Discovery

Next Generation of Spontaneous Diabetic Model of ZDSD Rats with Intact Leptin Signaling Develop Cardiac Dysfunction and Compromised Cardiac Reserve

Gao Sun, Guodong Zhang, and Jim Wang
CrownBio 2018. Poster 421-P: ZDSD Rat Preclinical Model for Cardiomyopathy Drug Discovery
Cardiomyopathy is the leading cause of morbidity and mortality among diabetes and obesity related complications. Diabetic cardiomyopathy is characterized by cardiac hypertrophy, followed by thinning of the cardiac walls (with a decline in both systolic and diastolic function), which ultimately leads to heart failure.

The development of new treatments for diabetic cardiomyopathy is hampered by a lack of preclinical rodent models which fully capture the phenotypes of the disease. To help in the development of new drugs for diabetic cardiomyopathy, next generation preclinical models need to be validated and characterized with regards to their cardiac function.

This poster details the evaluation of cardiac function and reserve during the development of metabolic syndrome in the ZDSD rat, which is a novel preclinical model of type 2 diabetes with intact leptin signaling, which closely mimics the development of human disease.

Read this Poster to Discover:

  • That ZDSD rats, which carry multiple dysmetabolic phenotypes, are spontaneously hypertensive with reduction in LV function and cardiac reserve
  • That these cardiac function alterations resemble ultrasonic symptoms of diabetic cardiomyopathy in patients
  • How the ZDSD rat may serve as a suitable preclinical model for the evaluation of therapeutic approaches to treat cardiomyopathy with the presence of metabolic syndrome

Download the Poster Now!

Get Your Copy!

Your privacy is important to us.
We'll never share your information.

SHARE THIS